Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
about
Onto better TRAILs for cancer treatmentMarine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)Getting TRAIL back on track for cancer therapyRNA Regulation by Poly(ADP-Ribose) PolymerasesER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosisHypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency.Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKTDR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.H-Ras regulation of TRAIL death receptor mediated apoptosisTRAIL in cancer therapy: present and future challenges.Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formationThe TRAIL of oncogenes to apoptosis.PARP13 regulates cellular mRNA post-transcriptionally and functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript.ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins.Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes.Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNKInterleukin-1 receptor-associated kinase-2 (IRAK2) is a critical mediator of endoplasmic reticulum (ER) stress signalingRole of decoy molecules in neuronal ischemic preconditioning.Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC levelCombination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.Targeting AML through DR4 with a novel variant of rhTRAILRegulating TRAIL receptor-induced cell death at the membrane : a deadly discussionRecently confirmed apoptosis-inducing lead compounds isolated from marine sponge of potential relevance in cancer treatment.Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.Fractional killing arises from cell-to-cell variability in overcoming a caspase activity thresholdCardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins.Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells.The role of TRAIL death receptors in the treatment of hematological malignancies.Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells.
P2860
Q26768160-5B680604-4ACB-417B-9393-771766E80ACDQ26859211-0EF541DD-5296-424F-B1E8-D4A28A5DE7B1Q27027460-33B690BD-283A-4F46-B680-0438B27DC1A3Q28080877-ACBEE5DE-4926-451E-BBB2-29AB6E37B675Q28386923-A8EF4133-0206-4C00-9A36-CE00D56B01A7Q33637916-2D0A94B5-AB55-49FB-83D1-133E59368C21Q33695003-8BC7C024-00F0-4BC7-94BC-0A265FB2B02AQ33723716-1EF245F6-EA7B-41C1-A683-7B170E210752Q33726537-EAC75427-F8C5-4C99-8225-C8A13812B568Q33805582-DCB202D1-4A94-42F4-BD22-FF7A5F29DAE6Q33841579-7D772B89-8BE5-4134-B062-0A7D7A2279E0Q33912038-F56125BE-0B20-4A5F-A5B3-211B6A97EEA0Q33916314-16813996-917D-4381-ABDB-65E23D0DAE32Q33939106-EB9251C0-8D4A-424A-BFBC-319C41754849Q34104161-B1F41B46-9B5F-4D4F-98BD-DE11B80C4E14Q34291312-1A551FEF-FC56-4F30-99B7-8EAEF6E2DAAFQ34334395-789C35BC-A7A4-4FFE-BC85-CD7FB944C0B6Q34354511-057A8795-FDEA-4A50-929D-BC8CED93F398Q34493442-10C6595C-790D-47A8-AB51-AD3EDD0D21CCQ34496536-26CFA942-CDE4-49E5-A4AA-4E817611A173Q34496935-4B889ACD-584D-46CB-85CD-9A7FFE71C051Q34561798-A7B0A973-4810-4919-905D-4BEB5446AE09Q34568521-3E42AE40-690D-4825-9CE0-BEA861C73E88Q34749542-6F1E160A-B4B7-4838-84A1-C449266B03B1Q34756874-7694BE69-35ED-44B3-BF05-CC7B16E413B9Q35051505-553479E6-585A-4884-886D-D084B30D3567Q35327231-4F60E64B-B92B-4AE1-9DDA-F312286DC66DQ35377418-D2A2A3E3-29A0-42CD-B86B-F9F688BF5BBDQ35480734-B84FF534-8EE1-4160-95B1-C196886BED3BQ35578368-D4BDF471-9114-4A44-9F24-B088E1A30F81Q35643014-EDE8DFF5-4620-48D6-A449-1B7D7BEC9B0AQ35705510-EF97ECD9-C931-4B2D-BB1A-20C9EB140529Q35859789-C9DD2F50-4EAA-48D4-8F07-2A942EB58AA0Q35863285-6463D951-E27F-46AE-B65F-3BB0A12540F1Q36215003-C7FF1ECF-662D-4117-8ED2-6F117D4BD869Q36338510-92F8D99E-E663-4577-B062-B899B0E04E89Q36731174-381ACBC6-05B5-4FE0-B835-8BC9BD0CDBF9Q37029417-0227C9C3-625E-49A5-A75C-4595A17E65E8Q37059750-C492CDEF-C151-42F8-8344-C36298A9E179Q37075014-3E92FA8D-2937-44EC-9E98-E65C24A5A583
P2860
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
@ast
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
@en
type
label
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
@ast
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
@en
prefLabel
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
@ast
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
@en
P2860
P50
P356
P1476
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
@en
P2093
Alexandre Morizot
P2860
P304
P356
10.1128/MCB.00520-06
P407
P577
2006-10-01T00:00:00Z